Optimize, execute and analyze trials that accelerate clinical development and pathways to approval for AD therapies with a trusted CRO.
Read the white paper.
The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of discussions with substantial ramifications for drugmakers. It’s likely to be challenged in court, however.
The president claimed his “most-favored nation” proposal would reduce some pharmaceutical prices by as much as 80%, but the details on how that will happen are unclear.
ADARx Pharmaceuticals will work with AbbVie to make RNA interference medicines for a variety of disease areas, including neurology, immunology and cancer.
Flexible supply chain models with on-demand packaging to support patient-focused clinical supply, based on actual site and patient demand. Discover more about DLS.
A gene editing drug custom-made for a critically ill baby showed that, for some ultra-rare diseases, it’s possible to design and test a new CRISPR medicine in just a few months.
Amidst the rise of biosimilars, market access challenges have become the definitive roadblock to bringing novel therapeutics to market. Learn how to build a market access plan in this webinar.
